Cargando…

The International Vitreoretinal B-Cell Lymphoma Registry: a protocol paper

INTRODUCTION: Vitreoretinal lymphoma is a rare ocular cancer with high morbidity and mortality despite treatment. Diagnosis by cytopathology is often delayed, and various molecular and image-based investigations have been developed. Diverse treatments are used, but there is a limited medical evidenc...

Descripción completa

Detalles Bibliográficos
Autores principales: Smith, Justine R, Farrall, Alexandra L, Davis, Janet L, de Boer, Joke H, Hall, Anthony J, Mochizuki, Manabu, Sen, H Nida, Takase, Hiroshi, ten Dam-van Loon, Ninette H, Touitou, Valérie, Vasconcelos-Santos, Daniel V, Wilson, David J, Yeh, Steven, Radford, Mark H B
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9341180/
https://www.ncbi.nlm.nih.gov/pubmed/35902200
http://dx.doi.org/10.1136/bmjopen-2021-060701
_version_ 1784760557817036800
author Smith, Justine R
Farrall, Alexandra L
Davis, Janet L
de Boer, Joke H
Hall, Anthony J
Mochizuki, Manabu
Sen, H Nida
Takase, Hiroshi
ten Dam-van Loon, Ninette H
Touitou, Valérie
Vasconcelos-Santos, Daniel V
Wilson, David J
Yeh, Steven
Radford, Mark H B
author_facet Smith, Justine R
Farrall, Alexandra L
Davis, Janet L
de Boer, Joke H
Hall, Anthony J
Mochizuki, Manabu
Sen, H Nida
Takase, Hiroshi
ten Dam-van Loon, Ninette H
Touitou, Valérie
Vasconcelos-Santos, Daniel V
Wilson, David J
Yeh, Steven
Radford, Mark H B
author_sort Smith, Justine R
collection PubMed
description INTRODUCTION: Vitreoretinal lymphoma is a rare ocular cancer with high morbidity and mortality despite treatment. Diagnosis by cytopathology is often delayed, and various molecular and image-based investigations have been developed. Diverse treatments are used, but there is a limited medical evidence to differentiate their effectiveness. We designed an international registry that would collect diagnostic, treatment and outcomes data, to establish new evidence for the management of this cancer. METHODS AND ANALYSIS: The International Vitreoretinal B-Cell Lymphoma Registry will accrue data retrospectively for individuals aged 18 years or older, diagnosed with new or recurrent vitreoretinal B-cell lymphoma on or after 1 January 2020. A steering committee of subspecialised ophthalmologists identified 20 key clinical data items that describe patient demographics, tissue involvements, diagnostic testing, ocular and systemic treatments and treatment complications, and visual acuity and survival outcomes. Customised software was designed to permit collection of these data across a single baseline and multiple follow-up forms. The platform collects data without identifiers and at 3 month reporting intervals. Outcomes of the project will include: (1) descriptions of clinical presentations, and diagnostic and therapeutic preferences; (2) associations between clinical presentations, and diagnostics and treatments, and between diagnostics and treatments (assessed by ORs with 95% CIs); and (3) estimations of rates of vision loss, and progression-free and overall survival (assessed by Kaplan-Meier estimates). ETHICS AND DISSEMINATION: The registry has received Australia-wide approval by a national human research ethics committee. Sites located outside Australia are required to seek local human research ethics review. Results generated through the registry will be disseminated primarily by peer-reviewed publications that are expected to inform clinical practice, as well as educational materials.
format Online
Article
Text
id pubmed-9341180
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-93411802022-08-17 The International Vitreoretinal B-Cell Lymphoma Registry: a protocol paper Smith, Justine R Farrall, Alexandra L Davis, Janet L de Boer, Joke H Hall, Anthony J Mochizuki, Manabu Sen, H Nida Takase, Hiroshi ten Dam-van Loon, Ninette H Touitou, Valérie Vasconcelos-Santos, Daniel V Wilson, David J Yeh, Steven Radford, Mark H B BMJ Open Ophthalmology INTRODUCTION: Vitreoretinal lymphoma is a rare ocular cancer with high morbidity and mortality despite treatment. Diagnosis by cytopathology is often delayed, and various molecular and image-based investigations have been developed. Diverse treatments are used, but there is a limited medical evidence to differentiate their effectiveness. We designed an international registry that would collect diagnostic, treatment and outcomes data, to establish new evidence for the management of this cancer. METHODS AND ANALYSIS: The International Vitreoretinal B-Cell Lymphoma Registry will accrue data retrospectively for individuals aged 18 years or older, diagnosed with new or recurrent vitreoretinal B-cell lymphoma on or after 1 January 2020. A steering committee of subspecialised ophthalmologists identified 20 key clinical data items that describe patient demographics, tissue involvements, diagnostic testing, ocular and systemic treatments and treatment complications, and visual acuity and survival outcomes. Customised software was designed to permit collection of these data across a single baseline and multiple follow-up forms. The platform collects data without identifiers and at 3 month reporting intervals. Outcomes of the project will include: (1) descriptions of clinical presentations, and diagnostic and therapeutic preferences; (2) associations between clinical presentations, and diagnostics and treatments, and between diagnostics and treatments (assessed by ORs with 95% CIs); and (3) estimations of rates of vision loss, and progression-free and overall survival (assessed by Kaplan-Meier estimates). ETHICS AND DISSEMINATION: The registry has received Australia-wide approval by a national human research ethics committee. Sites located outside Australia are required to seek local human research ethics review. Results generated through the registry will be disseminated primarily by peer-reviewed publications that are expected to inform clinical practice, as well as educational materials. BMJ Publishing Group 2022-07-28 /pmc/articles/PMC9341180/ /pubmed/35902200 http://dx.doi.org/10.1136/bmjopen-2021-060701 Text en © Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Ophthalmology
Smith, Justine R
Farrall, Alexandra L
Davis, Janet L
de Boer, Joke H
Hall, Anthony J
Mochizuki, Manabu
Sen, H Nida
Takase, Hiroshi
ten Dam-van Loon, Ninette H
Touitou, Valérie
Vasconcelos-Santos, Daniel V
Wilson, David J
Yeh, Steven
Radford, Mark H B
The International Vitreoretinal B-Cell Lymphoma Registry: a protocol paper
title The International Vitreoretinal B-Cell Lymphoma Registry: a protocol paper
title_full The International Vitreoretinal B-Cell Lymphoma Registry: a protocol paper
title_fullStr The International Vitreoretinal B-Cell Lymphoma Registry: a protocol paper
title_full_unstemmed The International Vitreoretinal B-Cell Lymphoma Registry: a protocol paper
title_short The International Vitreoretinal B-Cell Lymphoma Registry: a protocol paper
title_sort international vitreoretinal b-cell lymphoma registry: a protocol paper
topic Ophthalmology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9341180/
https://www.ncbi.nlm.nih.gov/pubmed/35902200
http://dx.doi.org/10.1136/bmjopen-2021-060701
work_keys_str_mv AT smithjustiner theinternationalvitreoretinalbcelllymphomaregistryaprotocolpaper
AT farrallalexandral theinternationalvitreoretinalbcelllymphomaregistryaprotocolpaper
AT davisjanetl theinternationalvitreoretinalbcelllymphomaregistryaprotocolpaper
AT deboerjokeh theinternationalvitreoretinalbcelllymphomaregistryaprotocolpaper
AT hallanthonyj theinternationalvitreoretinalbcelllymphomaregistryaprotocolpaper
AT mochizukimanabu theinternationalvitreoretinalbcelllymphomaregistryaprotocolpaper
AT senhnida theinternationalvitreoretinalbcelllymphomaregistryaprotocolpaper
AT takasehiroshi theinternationalvitreoretinalbcelllymphomaregistryaprotocolpaper
AT tendamvanloonninetteh theinternationalvitreoretinalbcelllymphomaregistryaprotocolpaper
AT touitouvalerie theinternationalvitreoretinalbcelllymphomaregistryaprotocolpaper
AT vasconcelossantosdanielv theinternationalvitreoretinalbcelllymphomaregistryaprotocolpaper
AT wilsondavidj theinternationalvitreoretinalbcelllymphomaregistryaprotocolpaper
AT yehsteven theinternationalvitreoretinalbcelllymphomaregistryaprotocolpaper
AT radfordmarkhb theinternationalvitreoretinalbcelllymphomaregistryaprotocolpaper
AT smithjustiner internationalvitreoretinalbcelllymphomaregistryaprotocolpaper
AT farrallalexandral internationalvitreoretinalbcelllymphomaregistryaprotocolpaper
AT davisjanetl internationalvitreoretinalbcelllymphomaregistryaprotocolpaper
AT deboerjokeh internationalvitreoretinalbcelllymphomaregistryaprotocolpaper
AT hallanthonyj internationalvitreoretinalbcelllymphomaregistryaprotocolpaper
AT mochizukimanabu internationalvitreoretinalbcelllymphomaregistryaprotocolpaper
AT senhnida internationalvitreoretinalbcelllymphomaregistryaprotocolpaper
AT takasehiroshi internationalvitreoretinalbcelllymphomaregistryaprotocolpaper
AT tendamvanloonninetteh internationalvitreoretinalbcelllymphomaregistryaprotocolpaper
AT touitouvalerie internationalvitreoretinalbcelllymphomaregistryaprotocolpaper
AT vasconcelossantosdanielv internationalvitreoretinalbcelllymphomaregistryaprotocolpaper
AT wilsondavidj internationalvitreoretinalbcelllymphomaregistryaprotocolpaper
AT yehsteven internationalvitreoretinalbcelllymphomaregistryaprotocolpaper
AT radfordmarkhb internationalvitreoretinalbcelllymphomaregistryaprotocolpaper